[go: up one dir, main page]

RU2008111144A - METHODS FOR MODELING AND INHIBITING CANCER CELL MIGRATION - Google Patents

METHODS FOR MODELING AND INHIBITING CANCER CELL MIGRATION Download PDF

Info

Publication number
RU2008111144A
RU2008111144A RU2008111144/14A RU2008111144A RU2008111144A RU 2008111144 A RU2008111144 A RU 2008111144A RU 2008111144/14 A RU2008111144/14 A RU 2008111144/14A RU 2008111144 A RU2008111144 A RU 2008111144A RU 2008111144 A RU2008111144 A RU 2008111144A
Authority
RU
Russia
Prior art keywords
cell
lymphocytic
fusion
nature
carcinoma
Prior art date
Application number
RU2008111144/14A
Other languages
Russian (ru)
Other versions
RU2404805C2 (en
Inventor
Дэвид Т. ХАРРИС (US)
Дэвид Т. ХАРРИС
Том С. ЦАНГ (US)
Том С. ЦАНГ
Ксиангуи ХЕ (CN)
Ксиангуи ХЕ
Брайан Л. ПИПЕС (US)
Брайан Л. ПИПЕС
Линда С. МЕАДЕ-ТОЛЛИН (US)
Линда С. МЕАДЕ-ТОЛЛИН
Original Assignee
Аризона Боард Оф Риджентс Он Бехаф Оф Зе Юниверсити Оф Аризона (Us)
Аризона Боард Оф Риджентс Он Бехаф Оф Зе Юниверсити Оф Аризона
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аризона Боард Оф Риджентс Он Бехаф Оф Зе Юниверсити Оф Аризона (Us), Аризона Боард Оф Риджентс Он Бехаф Оф Зе Юниверсити Оф Аризона filed Critical Аризона Боард Оф Риджентс Он Бехаф Оф Зе Юниверсити Оф Аризона (Us)
Publication of RU2008111144A publication Critical patent/RU2008111144A/en
Application granted granted Critical
Publication of RU2404805C2 publication Critical patent/RU2404805C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Способ моделирования миграции раковых клеток нелимфоцитарной природы, содержащий стадии: ! (а) получение стволовой клетки из костного мозга; ! (б) получение генетически измененной клетки нелимфоцитарной природы; ! (в) слияние стволовой клетки костного мозга с генетически измененной клеткой, при этом образуется слитая клетка нелимфоцитарной природы; и ! (г) измерение показателя миграции указанной слитой клетки нелимфоцитарной природы. ! 2. Способ по п.1, отличающийся тем, что стадии (а) и (б) включают получение или культивирование слитой клетки нелимфоцитарной природы при использовании полученного ранее слияния стволовой клетки костного мозга с генетически измененной клеткой нелимфоцитарной природы. ! 3. Способ по п.1, отличающийся тем, что стадия (г) включает in vitro анализ методом царапин, насечек, штрихов. ! 4. Способ по п.1, отличающийся тем, что стадию (г) проводят in vivo. ! 5. Способ по п.1, отличающийся тем, что указанная клетка на стадии (б) имеет эпителиальное происхождение. ! 6. Способ по п.1, отличающийся тем, что указанная клетка на стадии (б) происходит из карциномы или карциномной клеточной линии. ! 7. Способ скрининга действия биологического или химического агента на миграцию опухолевых клеток нелимфоцитарной природы, включающий стадии ! (а) получение слитой клетки, образующейся при слиянии стволовой клетки костного мозга с генетически измененной клеткой нелимфоцитарной природы; ! (б) контактирование слитой клетки с биологическим или химическим агентом; и ! (в) определение, стимулируется ли, ингибируется ли или не изменяется миграция опухолевой клетки нелимфоцитарной природы. ! 8. Способ по п.7, отличающийся тем, что указан1. A method for simulating the migration of cancer cells of a non-lymphocytic nature, comprising the steps of:! (a) receiving stem cells from bone marrow; ! (b) obtaining a genetically modified cell of non-lymphocytic nature; ! (c) the fusion of a bone marrow stem cell with a genetically modified cell, and a fusion cell of non-lymphocytic nature is formed; and! (d) measuring a migration index of said fusion cell of a non-lymphocytic nature. ! 2. The method according to claim 1, characterized in that stages (a) and (b) include obtaining or cultivating a non-lymphocytic fusion cell using the previously obtained fusion of a bone marrow stem cell with a genetically modified non-lymphocytic cell. ! 3. The method according to claim 1, characterized in that stage (g) includes in vitro analysis by scratching, notches, strokes. ! 4. The method according to claim 1, characterized in that stage (g) is carried out in vivo. ! 5. The method according to claim 1, characterized in that said cell in stage (b) has an epithelial origin. ! 6. The method according to claim 1, characterized in that said cell in step (b) is derived from a carcinoma or a carcinoma cell line. ! 7. A method for screening the action of a biological or chemical agent on the migration of tumor cells of a non-lymphocytic nature, comprising the steps! (a) obtaining a fused cell resulting from the fusion of a bone marrow stem cell with a genetically modified non-lymphocytic cell; ! (b) contacting the fused cell with a biological or chemical agent; and! (c) determining whether non-lymphocytic tumor cell migration is inhibited, or does not change. ! 8. The method according to claim 7, characterized in that it is specified

Claims (23)

1. Способ моделирования миграции раковых клеток нелимфоцитарной природы, содержащий стадии:1. A method for simulating the migration of cancer cells of a non-lymphocytic nature, comprising the steps of: (а) получение стволовой клетки из костного мозга;(a) obtaining stem cells from bone marrow; (б) получение генетически измененной клетки нелимфоцитарной природы;(b) obtaining a genetically modified cell of non-lymphocytic nature; (в) слияние стволовой клетки костного мозга с генетически измененной клеткой, при этом образуется слитая клетка нелимфоцитарной природы; и(c) the fusion of a bone marrow stem cell with a genetically modified cell, and a fusion cell of a non-lymphocytic nature is formed; and (г) измерение показателя миграции указанной слитой клетки нелимфоцитарной природы.(d) measuring a migration index of said fusion cell of a non-lymphocytic nature. 2. Способ по п.1, отличающийся тем, что стадии (а) и (б) включают получение или культивирование слитой клетки нелимфоцитарной природы при использовании полученного ранее слияния стволовой клетки костного мозга с генетически измененной клеткой нелимфоцитарной природы.2. The method according to claim 1, characterized in that stages (a) and (b) include obtaining or cultivating a non-lymphocytic fusion cell using the previously obtained fusion of a bone marrow stem cell with a genetically modified non-lymphocytic cell. 3. Способ по п.1, отличающийся тем, что стадия (г) включает in vitro анализ методом царапин, насечек, штрихов.3. The method according to claim 1, characterized in that stage (g) includes in vitro analysis by scratching, notches, strokes. 4. Способ по п.1, отличающийся тем, что стадию (г) проводят in vivo.4. The method according to claim 1, characterized in that stage (g) is carried out in vivo. 5. Способ по п.1, отличающийся тем, что указанная клетка на стадии (б) имеет эпителиальное происхождение.5. The method according to claim 1, characterized in that said cell in stage (b) has an epithelial origin. 6. Способ по п.1, отличающийся тем, что указанная клетка на стадии (б) происходит из карциномы или карциномной клеточной линии.6. The method according to claim 1, characterized in that said cell in step (b) is derived from a carcinoma or a carcinoma cell line. 7. Способ скрининга действия биологического или химического агента на миграцию опухолевых клеток нелимфоцитарной природы, включающий стадии7. A method for screening the action of a biological or chemical agent on the migration of non-lymphocytic tumor cells, comprising the steps of (а) получение слитой клетки, образующейся при слиянии стволовой клетки костного мозга с генетически измененной клеткой нелимфоцитарной природы;(a) obtaining a fused cell resulting from the fusion of a bone marrow stem cell with a genetically modified non-lymphocytic cell; (б) контактирование слитой клетки с биологическим или химическим агентом; и(b) contacting the fused cell with a biological or chemical agent; and (в) определение, стимулируется ли, ингибируется ли или не изменяется миграция опухолевой клетки нелимфоцитарной природы.(c) determining whether non-lymphocytic tumor cell migration is inhibited, or does not change. 8. Способ по п.7, отличающийся тем, что указанный биологический или химический агент представляет собой антитело против убиквитина.8. The method according to claim 7, characterized in that said biological or chemical agent is an anti-ubiquitin antibody. 9. Способ по п.8, отличающийся тем, что указанное антитело представляет собой MEL-14.9. The method of claim 8, wherein said antibody is MEL-14. 10. Способ по п.8, отличающийся тем, что указанное антитело выбирают из группы, состоящей из антител 14372 и 10С2-2.10. The method of claim 8, wherein said antibody is selected from the group consisting of antibodies 14372 and 10C2-2. 11. Способ по п.7, отличающийся тем, что стадия (а) включает получение генетически измененной клетки кожи, молочной железы или предстательной железы.11. The method according to claim 7, characterized in that stage (a) includes obtaining a genetically modified skin cell, breast or prostate gland. 12. Способ по п.7, отличающийся тем, что стадию (б) проводят in vivo.12. The method according to claim 7, characterized in that stage (b) is carried out in vivo. 13. Способ по п.7, отличающийся тем, что стадия (а) включает получение генетически измененной клетки из карциномы или карциномной клеточной линии.13. The method according to claim 7, characterized in that stage (a) includes obtaining a genetically modified cell from a carcinoma or a carcinoma cell line. 14. Способ по п.13, отличающийся тем, что указанная карциномная клетка является клеткой человеческого происхождения.14. The method according to item 13, wherein the specified carcinoma cell is a cell of human origin. 15. Способ по п.13, отличающийся тем, что указанную карциномную клетку выбирают из группы, состоящей из клеток молочной железы, предстательной железы и кожи.15. The method according to item 13, wherein the specified carcinoma cell is selected from the group consisting of cells of the breast, prostate and skin. 16. Способ ингибирования миграции опухолевых клеток нелимфоцитарной природы, заключающийся в контактировании опухолевой клетки нелимфоцитарной природы с эффективным количеством антитела против убиквитина.16. A method of inhibiting the migration of tumor cells of a non-lymphocytic nature, which consists in contacting a tumor cell of a non-lymphocytic nature with an effective amount of an anti-ubiquitin antibody. 17. Способ по п.16, дополнительно включающий стадию подтверждения присутствия слитых клеток в указанной нелимфоцитарной опухоли перед указанным контактированием.17. The method according to clause 16, further comprising the step of confirming the presence of fused cells in said non-lymphocytic tumor before said contacting. 18. Способ по п.16, отличающийся тем, что указанное антитело представляет собой MEL-14.18. The method according to clause 16, wherein said antibody is MEL-14. 19. Способ по п.16, отличающийся тем, что указанное антитело выбирают из группы, состоящей из антител 14372 и 10С2-2.19. The method according to clause 16, wherein said antibody is selected from the group consisting of antibodies 14372 and 10C2-2. 20. Способ по п.16, отличающийся тем, что указанное контактирование проводят in vitro.20. The method according to clause 16, wherein said contacting is carried out in vitro. 21. Способ по п.16, отличающийся тем, что указанная опухолевая клетка нелимфоцитарной природы происходит из карциномы или карциномной клеточной линии.21. The method according to clause 16, wherein said non-lymphocytic tumor cell originates from a carcinoma or a carcinoma cell line. 22. Способ по п.21, отличающийся тем, что указанная карциномная клетка является клеткой человеческого происхождения.22. The method according to item 21, wherein the specified carcinoma cell is a cell of human origin. 23. Способ по п.21, отличающийся тем, что указанную карциномную клетку выбирают из группы, состоящей из клеток молочной железы, предстательной железы и кожи. 23. The method according to item 21, wherein the specified carcinoma cell is selected from the group consisting of cells of the breast, prostate and skin.
RU2008111144/14A 2005-08-25 2006-08-25 Method of inhibiting migration of cancer cells RU2404805C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71124905P 2005-08-25 2005-08-25
US60/711,249 2005-08-25

Publications (2)

Publication Number Publication Date
RU2008111144A true RU2008111144A (en) 2009-09-27
RU2404805C2 RU2404805C2 (en) 2010-11-27

Family

ID=37772481

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008111144/14A RU2404805C2 (en) 2005-08-25 2006-08-25 Method of inhibiting migration of cancer cells

Country Status (15)

Country Link
US (2) US8158126B2 (en)
EP (2) EP1924685B1 (en)
JP (2) JP5400381B2 (en)
KR (2) KR101413048B1 (en)
CN (2) CN103212071B (en)
AU (2) AU2006282853B2 (en)
BR (1) BRPI0615081A2 (en)
CA (2) CA2620616C (en)
ES (2) ES2523857T3 (en)
HU (1) HUE025948T2 (en)
IL (2) IL189674A (en)
RU (1) RU2404805C2 (en)
SG (1) SG152229A1 (en)
WO (1) WO2007025216A2 (en)
ZA (1) ZA200802512B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369591C (en) 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
ES2523857T3 (en) * 2005-08-25 2014-12-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Stem cell fusion carcinogenesis model
US20120295344A1 (en) * 2006-08-25 2012-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem Cell Fusion Model of Carcinogenesis
SG165397A1 (en) 2005-09-19 2010-10-28 Emisphere Tech Inc Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid
EP1973948B1 (en) 2005-12-15 2015-02-11 Genentech, Inc. Methods and compositions for targeting polyubiquitin
US8133488B2 (en) 2008-01-18 2012-03-13 Genentech, Inc. Methods and compositions for targeting polyubiquitin
US8178307B2 (en) * 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
JP6002660B2 (en) 2010-04-15 2016-10-05 ジェネンテック， インコーポレイテッド Anti-ubiquitin antibodies and methods of use
SG191048A1 (en) 2010-12-06 2013-07-31 Cure Cancer Worldwide Corp Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
BR112014002716A2 (en) 2011-08-05 2017-06-13 Genentech Inc anti-polyubiquitin antibodies and methods of use
CN110391025A (en) * 2018-04-19 2019-10-29 清华大学 A kind of artificial intelligence modeling method towards macro microcosmic various dimensions early gastric caacer risk assessment
US11052041B1 (en) 2020-10-01 2021-07-06 King Abdulaziz University Nanotechnology-based nostril drops for relief of respiratory ailments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462111A4 (en) * 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
US6007816A (en) 1989-03-17 1999-12-28 Fred Hutchinson Cancer Research Center Methods of using CD44-specific antibodies
AU6407094A (en) * 1993-03-19 1994-10-11 Darell D. Bigner Method of treating tumors with antibodies
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
CA2235245A1 (en) 1995-10-17 1997-04-24 Dovetail Technologies, Inc Low molecular weight cell, bone marrow and immune stimulants
CA2383432A1 (en) * 1999-08-25 2001-12-06 Altarex Corp. Therapeutic immune condition compositions and methods
US20050181381A1 (en) * 2003-04-18 2005-08-18 University Of Massachusetts Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer
CN1302102C (en) * 2003-12-29 2007-02-28 中国医学科学院血液学研究所 Method for preparing megakaryocytic preparation by amplifying macronucleus ancestral cell and mature megacaryocyte and use
US20060033366A1 (en) 2004-08-11 2006-02-16 Jeffrey Vernon M Headrest display device
MX2008000974A (en) * 2005-07-22 2008-03-27 Univ California Heparin compostions and selectin inhibition.
ES2523857T3 (en) * 2005-08-25 2014-12-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Stem cell fusion carcinogenesis model

Also Published As

Publication number Publication date
AU2006282853B2 (en) 2011-01-20
KR20080048499A (en) 2008-06-02
ZA200802512B (en) 2009-01-28
CA2620616C (en) 2016-06-14
ES2523857T3 (en) 2014-12-02
EP1924685A4 (en) 2009-03-04
CN103212071A (en) 2013-07-24
ES2552101T3 (en) 2015-11-25
EP1924685B1 (en) 2014-08-27
US20090016961A1 (en) 2009-01-15
BRPI0615081A2 (en) 2011-05-03
US8158126B2 (en) 2012-04-17
WO2007025216A3 (en) 2007-07-05
KR20130020738A (en) 2013-02-27
JP2011225613A (en) 2011-11-10
CN103212071B (en) 2017-12-12
EP1924685A2 (en) 2008-05-28
AU2011201605A1 (en) 2011-04-28
US8758755B2 (en) 2014-06-24
JP5597171B2 (en) 2014-10-01
KR101413048B1 (en) 2014-06-30
US20120201808A1 (en) 2012-08-09
EP2363146A1 (en) 2011-09-07
HK1161976A1 (en) 2012-08-17
AU2006282853A1 (en) 2007-03-01
SG152229A1 (en) 2009-05-29
RU2404805C2 (en) 2010-11-27
JP5400381B2 (en) 2014-01-29
AU2011201605B2 (en) 2012-12-20
IL189674A0 (en) 2008-06-05
WO2007025216A2 (en) 2007-03-01
CA2808168C (en) 2018-06-12
CA2620616A1 (en) 2007-03-01
JP2009505664A (en) 2009-02-12
HUE025948T2 (en) 2016-05-30
IL222468A (en) 2015-10-29
EP2363146B1 (en) 2015-06-24
CN101273124A (en) 2008-09-24
KR101413055B1 (en) 2014-07-02
CN101273124B (en) 2013-05-08
CA2808168A1 (en) 2007-03-01
IL189674A (en) 2012-10-31

Similar Documents

Publication Publication Date Title
US11634753B2 (en) On-slide staining by primer extension
US11168350B2 (en) Highly-multiplexed fluorescent imaging
Shi et al. Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades
RU2008111144A (en) METHODS FOR MODELING AND INHIBITING CANCER CELL MIGRATION
CN103344760B (en) A kind of high flux method for immunohistochemical detection and Multi-example SABC check-out console
Carvalho et al. Systematics and historical biogeography of Neotropical foam-nesting frogs of the Adenomera heyeri clade (Leptodactylidae), with the description of six new Amazonian species
DE60204699D1 (en) METHOD FOR SELECTION OF CELLS EXPRESSING ANTIBODIES
Tollemar et al. Quantitative chromogenic immunohistochemical image analysis in cellprofiler software
KR101969847B1 (en) A method of sequential and multiple immunostaining for detection of various antigens in the same specimens
CN118995884A (en) Method for improving detection efficiency of in-situ ortho-position connection technology
Moncel et al. Preliminary results from the new excavations of the Middle and Upper Palaeolithic levels at Ortvale Klde-north chamber (South Caucasus Georgia)
CN102803968A (en) Esophageal cancer marker
Chin et al. Hydrogel stamping for rapid, multiplexed, point-of-care immunostaining of cells and tissues
ATE484577T1 (en) METHOD FOR IMMUNOTHERAPY OF TUMORS
JP5527573B2 (en) MCF7-derived cells
Flecher et al. Evaluation of immunophenotype and inflammation in canine mammary neoplasms with solid arrangement
ATE500275T1 (en) ANTIBODIES TO APRIL AS A BIOMARKER FOR EARLY PROGNOSIS IN LYMPHO PATIENTS
Frank et al. Holistic genetic barcoding reveals a lineage tree of tissue macrophage development
WO2023172623A3 (en) Antibody fragments and uses thereof for imaging cellular activity
Ilyina et al. Exploring the Heterogeneity of Cancer-Associated Fibroblasts via Development of Patient-Derived Cell Culture of Breast Cancer
CN106153754A (en) The differentially expressed protein of Alport syndrome patient's inductive pluripotent stem cells and analysis methods and applications
Šimečková et al. Multiparameter cytometric analysis of complex cellular response
Nilbert et al. Experiences from tissue microarray in soft tissue sarcomas
Pfeilstöcker Clonal hematopoiesis: Definitions and clinical implications in myeloid neoplasias and beyond
Grama Whole cell segmentation for the quantification of molecular biomarkers in histopathology samples from multiplex immunostaining and multi-spectral imaging

Legal Events

Date Code Title Description
FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20100125

MM4A The patent is invalid due to non-payment of fees

Effective date: 20190826